- Aytu BioPharma ( NASDAQ: AYTU ) said the U.S. Patent and Trademark Office issued a patent, a first for AR101/Enzastaurin.
- The U.S. patent No. 11,273,148 titled 'Targeted Epigenetic Therapy for Inherited Aortic Aneurism Condition,' covers methods for the targeted epigenetic therapy of inherited aortic aneurysm and other diseases with altered regulation of TGF? genes, including Ehlers-Danlos Syndrome, the company said in an Aug. 16 press release.
- Aytu added that it was the first issued patent supporting the portfolio and expires in August of 2038, if not extended.
- "This issued patent underpins the broad potential clinical application across numerous inherited vascular disorders, including vascular Ehlers-Danlos Syndrome ("VEDS"), for which we are advancing AR101 as an initial indication. We expect to progress the PREVEnt Trial in VEDS for AR101 and dose the first patient by early 2023," said Aytu CEO Josh Disbrow.
- AYTU +0.59% to $0.29 premarket Aug. 16
For further details see:
Aytu gets US patent for AR101/Enzastaurin for circulatory system disorders